Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.47 |
| ▸ | CTSD | P07339 | 16/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 14/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640268 | 0.87 | BACE1 (0.58) | BACE1CTSDBACE2 | |
| SCHEMBL3780604 | 0.86 | BACE1 (0.46) | BACE1CTSDBACE2MAPT | |
| SCHEMBL3636810 | 0.86 | BACE1 (0.46) | BACE1CTSDBACE2 | |
| SCHEMBL3847657 | 0.83 | BACE1 (0.47) | BACE1CTSDBACE2MAPT | |
| SCHEMBL3636245 | 0.83 | BACE1 (0.47) | BACE1BACE2 | |
| SCHEMBL3633229 | 0.83 | BACE1 (0.46) | BACE1CTSDBACE2 | |
| SCHEMBL3777045 | 0.80 | NPSR1 (0.30) | — | |
| SCHEMBL3243724 | 0.78 | KDM1A (0.40) | BACE1CTSDBACE2 | |
| SCHEMBL4398010 | 0.76 | TEK (0.36) | BACE1CTSDBACE2 | |
| SCHEMBL3240569 | 0.76 | BACE1 (0.32) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | claimed |
| EP-2155749-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | claimed |
| US-7629356-B2 | Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions | ASTRAZENECA AB (SE) | 2009-12-08 | — | — | US | claimed |
| US-20090233945-A9 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| WO-2009022961-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | claimed |
| US-20080287462-A1 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| EP-2155749-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-7629356-B2 | Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions | ASTRAZENECA AB (SE) | 2009-12-08 | — | — | US | disclosed |
| US-20090233945-A9 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| WO-2009022961-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
| US-20080287462-A1 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 44/4885BACE2 2/4885 |
| US-20090233945-A9 | NEW COMPOUNDS 834 | MAPT, PSEN1, PSEN2 | BACE1 4/4885CTSD 1386/4885BACE2 17/4885 |
| US-20080287462-A1 | NEW COMPOUNDS 834 | MAPT, PSEN1, PSEN2 | BACE1 4/4885CTSD 1386/4885BACE2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.